Bardy Diagnostics

What Bardy Diagnostics does

Bardy Diagnostics is a US-based developer of ambulatory cardiac monitoring technology, founded in 2013 by electrophysiologist Gust H. Bardy, M.D. The company's flagship product is the Carnation Ambulatory Monitor (CAM) Patch, a single-use, wire-free ECG patch designed for extended wear up to 14 days. The CAM Patch is placed along the sternum to optimize P-wave signal capture, addressing the limited atrial signal clarity that constrains conventional Holter and competing patch monitors. The company complements the device with the BDxCONNECT cloud-based patient management portal (HIPAA-compliant, ISO/IEC 27001 certified, with EHR integration API) and the proprietary CAM Report, a multi-field diagnostic report format that combines near-field, medium-field, and far-field R-R interval views, delivered within an average of under 48 hours after data upload.

The company monetizes through hardware sales of the CAM Patch and professional ECG analysis services performed by CRAT- and CCT-certified technicians (operated via Baxter's Independent Diagnostic Testing Facility), reimbursed under CPT codes for continuous cardiac monitoring of 48 hours to 15 days. An in-house convolutional neural network analyzes ECG recordings and R-R interval data to produce AF yes/no output every half-second, with published performance of 96.82% sensitivity and 99.86% specificity. Bardy sells primarily through a direct enterprise sales force targeting electrophysiologists, cardiologists, hospitals, and health systems, supported by clinical evidence from peer-reviewed head-to-head studies against Holter, Zio XT, and MCT.

Bardy Diagnostics operates from its Bellevue, Washington headquarters with operational centers in Houston TX, New Providence NJ, and Milpitas CA. In 2025, the company was acquired by Baxter International Inc. and now operates as a wholly-owned subsidiary, with all trademarks (BardyDx, CAM, BDx Design) owned by Baxter. The firm is private and does not publicly disclose revenue.

Name

Bardy Diagnostics

Legal name

Bardy Diagnostics, Inc.

Website

https://bardydx.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Bardy Diagnostics develops the P-wave centric Carnation Ambulatory Monitor (CAM) Patch, a wire-free ECG patch for up to 14-day cardiac monitoring, along with the BDxCONNECT portal and AI-powered AF detection. The company serves electrophysiologists, cardiologists, and hospitals in the United States and operates as a subsidiary of Baxter International Inc.

Ownership category

akta.pro rank

Product category

Ambulatory Cardiac Monitoring Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Laboratories (621511)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Services-Medical Laboratories (8071)

akta.pro primary industry

Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders) (HLAHACAB)

Keywords

• Ambulatory cardiac monitoring
• ECG patch monitor
• P-wave centric ECG
• Atrial fibrillation detection
• Remote cardiac monitoring

Headquarters

HQ city

Seattle

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Ambulatory Cardiac Monitoring Services: The company generates revenue through the sale of CAM Patch devices and associated monitoring services. Services include ECG data collection, analysis by certified ECG technicians (CRAT- and CCT-certified), and CAM Report generation. Reimbursement is based on CPT codes for continuous cardiac monitoring ranging from 48 hours to 15 days. The company provides billing support through its Customer Experience Team and offers multiple payment options for patients including phone, online, and mail payment methods.
2. ECG Analysis and Reporting Services: Revenue generated from professional ECG analysis services provided through Baxter's IDTF (Independent Diagnostic Testing Facility) within the United States. Reports are prepared by certified technicians and provided within 2 business days. Practices can also choose to analyze data using their own in-house ECG technicians.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

Bardy Diagnostics develops, manufactures, and sells the Carnation Ambulatory Monitor (CAM) Patch, a single-use P-wave centric ECG patch monitor for up to 14 days of continuous ambulatory recording, paired with the BDxCONNECT cloud-based patient management portal and the proprietary multi-field CAM Report. Revenue is generated from CAM Patch device sales and associated ECG analysis and reporting services performed by certified technicians, with reimbursement under CPT codes for continuous cardiac monitoring ranging from 48 hours to 15 days.

Product overview

Bardy Diagnostics offers a unified ambulatory cardiac monitoring solution centered on three integrated components: the Carnation Ambulatory Monitor (CAM) Patch (a P-wave centric ECG patch designed for up to 14-day extended wear), the BDxCONNECT cloud-based patient management and EHR integration portal, and the CAM Report system (delivering multi-view ECG analysis within 2 business days). These products work together as an end-to-end solution enabling patient monitoring, secure data upload, expert ECG analysis by certified technicians, and rapid clinical reporting.

Differentiator

Problem solved

Functional benefit

Brands

• CAM (Carnation Ambulatory Monitor): P-wave centric ECG patch monitor for ambulatory cardiac monitoring, designed to optimize P-wave signal capture and deliver high diagnostic accuracy for detecting arrhythmias.
• BDxCONNECT
• CAM Report

Products and services

• Carnation Ambulatory Monitor (CAM) Patch Lightweight, wire-free, single-use P-wave centric ECG patch monitor designed for up to 14 days of continuous ambulatory recording along the sternum, enabling patients to mark symptoms via a button and capturing every heartbeat with optimized atrial signal clarity for arrhythmia diagnosis.
• BDxCONNECT Portal HIPAA-compliant, ISO/IEC 27001-certified web-based patient management portal that supports patient registration, secure cloud transmission of patch monitor data, EHR integration via API, automatic notifications and alerts, and physician-editable online reporting.
• CAM Report Proprietary report format providing multiple diagnostic field views including Near-Field (8-second traditional view with R-R measurements), Medium-Field (56-second snapshot with 24 seconds pre/post episode), and Far-Field (40-minute R-R interval plot with 20 minutes pre/post) for enhanced arrhythmia diagnosis.
• ECG Analysis and Reporting Services Professional ECG analysis services performed by CRAT- and CCT-certified ECG technicians, with CAM Reports prepared within 2 business days and practices retaining the option to perform analysis using their own in-house ECG technicians.

Quantifiable outcome

• 96% of patients prefer CAM Patch over 3-lead standard Holter monitor
• +4 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

One partnership is on record.

• Baxter International Inc.coreOthersBardy Diagnostics is now part of Baxter. The company operates as Bardy Diagnostics, Inc., a subsidiary of Baxter International Inc. All trademarks (BardyDx, Bardy Diagnostics, BDx Design, CAM) are owned by Baxter International Inc. or its subsidiaries. The redirect page confirms 'Bardy Diagnostics is now part of Baxter.'

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• iRhythm Technologies: Public competitor (Zio patch) and the most direct peer — Bardy explicitly benchmarks clinical performance against Zio XT in published head-to-head studies, with overlapping electrophysiologist and cardiologist customer base.
• AliveCor: Maker of KardiaMobile ECG devices and AI-based AF detection algorithms; addresses the same electrophysiologist and cardiologist customer base for arrhythmia detection, though primarily via handheld/smartphone rather than patch form factor.

Emerging players

• SmartCardia: Offers a 7-lead wearable ECG patch with AI-powered arrhythmia detection; competes in ambulatory cardiac monitoring with overlapping remote-monitoring use cases targeting similar cardiology customers.
• HeartBeam: Developer of a credit-card-sized 3D ECG device for remote cardiac monitoring with AI-driven synthesis; competes in ambulatory arrhythmia detection with overlapping cardiology customer base.
• Cardiac Insight: Developer of the Cardea SOLO wearable ECG sensor and AI-based arrhythmia analysis; smaller, earlier-stage competitor in the same ambulatory cardiac patch category with overlapping electrophysiologist customers.

Regional players

• Compumedics: Australia-based developer of diagnostic ECG, Holter, and sleep monitoring systems; comparable in ambulatory cardiac monitoring hardware/services but primarily serves Asia-Pacific and select international markets rather than US focus of Bardy.

Broad incumbents

• GE Healthcare (MUSE Cardiology): Provides ECG management systems, Holter analysis, and cardiac diagnostic infrastructure widely deployed in hospitals; competes indirectly via incumbent ECG analysis platforms that integrate with hospital cardiology workflows.
• Boston Scientific (Preventice Solutions): Acquired Preventice Solutions (BodyGuardian) to enter remote cardiac monitoring; broader medtech incumbent now offering ambulatory ECG patch monitoring services directly competing with CAM Patch for cardiology accounts.
• Philips (BioTelemetry/Cardiac Monitoring): Acquired BioTelemetry to offer a broad portfolio including MCT (mobile cardiac telemetry) and ECG monitoring services; competes in ambulatory cardiac monitoring space though as part of a much larger diagnostic and patient monitoring portfolio.
• Hillrom / Baxter Patient Monitoring: Hillrom (now part of Baxter, parent of Bardy Diagnostics) provides Welch Allyn vital signs and bedside patient monitoring; potential channel partner and broader incumbent in hospital-based cardiac and patient monitoring.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCDOdasxsKLVvEE96WPbtnSA
• LinkedInlinkedin.com/company/17879425
• Xx.com/bardydx

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds4 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bardy Diagnostics